Clinical Trial Update: Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluates the efficacy and safety of a fixed-dose combination of empagliflozin and linagliptin in adults with type 2 diabetes, including trea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin / Linagliptin fixed-dose combination (empagliflozin/linagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2015-04-02